TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02687204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Real time dose adjustment
Description: Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
Study: NCT00887783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Navelbine
Description: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
Study: NCT04166526

Intervention type: DEVICE
Intervention: FDNIRS-DCS
Description: FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.

Intervention type: DEVICE
Intervention: FDNIRS-DCS
Description: FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.

Intervention type: DEVICE
Intervention: FDNIRS-DCS
Description: FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.

Intervention type: DEVICE
Intervention: MRI
Description: Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.

Intervention type: DEVICE
Intervention: MRI
Description: Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.

Intervention type: DEVICE
Intervention: MRI
Description: Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.

Intervention type: DEVICE
Intervention: MRI
Description: Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
Study: NCT04225078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide will be administered as a single oral dose at the expected therapeutic or supratherapeutic doses respectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching loperamide placebo capsules will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching loperamide placebo capsules will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching loperamide placebo capsules will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching loperamide placebo capsules will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablets will be administered orally.
Study: NCT01547689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Derived MSC
Description: 20 million cells per subject（0.5×10\^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
Study: NCT02065726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional counseling
Description: Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
Study: NCT04389996

Intervention type: OTHER
Intervention: No intervention
Description: Patients will be sent a survey incl. EORTC QLQ-C30
Study: NCT01718613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement
Study: NCT03709056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
Study: NCT00006006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study: NCT00887783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 66 Gy/33F
Description: irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
Study: NCT03011723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resource oriented music therapy
Description: 10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~1. Singing~2. Listening to live music~3. Listening to recorded music~4. Dancing~5. Conversations about memories/reminiscence~6. Exercising to music~7. Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)
Study: NCT03620630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: myCOPD
Description: myCOPD is a multi faceted web based application designed to support people with COPD in the Long term management of their COPD.
Study: NCT01530672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MBIO POC combined HIV syphilis test ( SnapEsi)
Description: Venipuncture for routine ANC screening plus additional for device validation purposes.
Study: NCT01286441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% EISO
Description: During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study: NCT01011322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
Study: NCT00887783

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 60 Gy/30F
Description: irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
Study: NCT02632409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT01286441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study: NCT02632409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01604980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein intake.
Description: protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
Study: NCT01286441

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% EISO
Description: During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% EISO
Description: During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
Study: NCT01011322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LT-02
Description: Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02101086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
Study: NCT00882622

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control/sham procedure
Description: Sham placement of the blood pressure cuff around the upper limb without inflation.
Study: NCT02387320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Care Toolkit
Description: The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
Study: NCT02101086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
Study: NCT01436201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered as subcutaneous injection
Study: NCT00524225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neumega (Oprelvekin, Interleukin 11, IL-11)
Description: 25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
Study: NCT00110890

Intervention type: DRUG
Group type: OTHER
Intervention: cinacalcet
Description: Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard of care
Description: Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
Study: NCT00887276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~1. 20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~2. 20 ml physiologic saline solution (placebo) (over 30 min)~3. 20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2. 2 capsules Placebo~3. 2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin;Amoxicillin
Description: intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~1. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~3. 2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1. 2 capsules Amoxicillin (0,5 g)~2. 2 capsules Amoxicillin (0,5 g)~3. 2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days
Study: NCT03437395

Intervention type: DEVICE
Group type: OTHER
Intervention: Balloon Brachytherapy
Description: The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.

Intervention type: RADIATION
Group type: OTHER
Intervention: 3D Conformal External Beam Irradiation
Description: 3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
Study: NCT03187990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA-11
Description: PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]PSMA-11
Description: PET/MRI with \[68Ga\]PSMA will be compared to mpMRI for biopsy guidance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PSMA-1007
Description: 18F-PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.
Study: NCT01404377

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: infiltration with ropivacaine solution
Description: Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
Study: NCT00212498

Intervention type: PROCEDURE
Intervention: Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies
Description: Blood sample
Study: NCT02839343

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: oxaliplatin IV, leucovorin IV and 5-FU IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: oxaliplatin IV, leucovorin IV and 5-FU IV
Study: NCT04785131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prune
Description: daily consumption of 50 grams prune.
Study: NCT01576822

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: This protocol will utilize a sauna as the primary method of detoxification.
Description: This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: This protocol will utilize a sauna as the primary method of detoxification.
Description: This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna).
Study: NCT03675152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft spinal brace
Description: Soft thoracolumbar brace worn 23 hours a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: thoracolumbar orthosis
Description: Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Excersice restriction
Description: Patients are only allowed to do isometrical excersices adviced by a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Excersice restriction
Description: Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
Study: NCT02000414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intraperitoneal daptomycin
Description: intraperitoneal daptomycin administartion and study of daptomycin kinetics
Study: NCT00897897

Intervention type: DEVICE
Group type: OTHER
Intervention: Philips MRI-guided HIFU system
Description: HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
Study: NCT02497677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circle of Security -Parenting
Description: The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care as Usual
Description: CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.